Tracks nemolizumab use in adolescents and adults with atopic dermatitis
Observes how nemolizumab works for moderate-to-severe atopic dermatitis in routine care.
Key facts
- Who runs it
- Galderma R&D
- Where
- Birmingham, Bridgend, Epsom, Harrogate, Harrow, Kings Lynn, Kingston upon Thames, Kirkcaldy, Leeds, Liverpool, London, Manchester, Metropolitan Borough of Wirral, Redhill, Sandbach, Sheffield, Southampton, Swansea, Watford, Wolverhampton, and York, United KingdomSee the 24 sitesAlso in 2 other countries, 84 sites
- Trial code
- Registry title
- Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Status
- Recruiting
- People taking part
- 1,000 people, planned
- Started
- 14 Jul 2025
- Expected to end
- 30 Nov 2027
- Type of study
- Observational
- Record updated
- 13 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for teenagers and adults with moderate-to-severe atopic dermatitis who are starting treatment with nemolizumab (Nemluvio®), as decided by their doctor.
- Age
- 12 years and older
- Sex
- All sexes can join.
- Disease stage
- Moderate-to-severe atopic dermatitis (AD).
- Earlier treatment
- Must not have received nemolizumab before. Must not have taken a drug in clinical development or under investigation in the 3 months before the start.
Main reasons for not taking part
- Has a contraindication to nemolizumab (Nemluvio®) under the local package label
- Took a drug under clinical development or investigation within 3 months before baseline
- Received nemolizumab before
- Cannot understand the consent form or complete the study questionnaires
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Participants who, according to the treating physician's decision and in line with the local package label, start treatment with nemolizumab (Nemluvio®)
- Adolescent and adult participants aged >=12 years with moderate-to-severe AD
- Participants who signed the written informed consent form (ICF) or had it signed by their legal representative
Who cannot take part
- Participants who received treatment with a drug under clinical development/investigation within 3 months prior to baseline
- Participants who received nemolizumab previously
- Have contraindication(s) for the use of nemolizumab (Nemluvio®) according to the local package label
- Participants who are mentally, physically, or linguistically unable to understand the content of the ICF and/or to complete the study questionnaires
Where in United Kingdom
Also in 2 other countries, 84 sites
- Birmingham, West MidlandsHospital not named in the registryContact: Galderma Research and DevelopmentTaking people
- BridgendHospital not named in the registryContact: Galderma Research and DevelopmentTaking people
- EpsomHospital not named in the registryContact: Galderma Research and DevelopmentTaking people
- Harrogate, North YorkshireHospital not named in the registryContact: Galderma Research and DevelopmentTaking people
- HarrowHospital not named in the registryContact: Galderma Research and DevelopmentTaking people
- Kings Lynn, NorfolkHospital not named in the registryContact: Galderma Research and DevelopmentTaking people
- Kingston upon ThamesHospital not named in the registryContact: Galderma Research and DevelopmentTaking people
- KirkcaldyHospital not named in the registryContact: Galderma Research and DevelopmentNot yet recruiting
- Leeds, West YorkshireHospital not named in the registryContact: Galderma Research and DevelopmentTaking people
- LiverpoolHospital not named in the registryContact: Galderma Research and DevelopmentTaking people
- LondonHospital not named in the registryContact: Galderma Research and DevelopmentTaking people
- London, HampshireHospital not named in the registryContact: Galderma Research and DevelopmentTaking people
- London, SurreyHospital not named in the registryContact: Galderma Research and DevelopmentTaking people
- LondonHospital not named in the registryContact: Galderma Research and DevelopmentTaking people
- ManchesterHospital not named in the registryContact: Galderma Research and DevelopmentTaking people
- Metropolitan Borough of WirralHospital not named in the registryContact: Galderma Research and DevelopmentTaking people
- RedhillHospital not named in the registryContact: Galderma Research and DevelopmentTaking people
- SandbachHospital not named in the registryContact: Galderma Research and DevelopmentTaking people
- Sheffield, South YorkshireHospital not named in the registryContact: Galderma Research and DevelopmentTaking people
- Southampton, HampshireHospital not named in the registryContact: Galderma Research and DevelopmentTaking people
- SwanseaHospital not named in the registryContact: Galderma Research and DevelopmentTaking people
- Watford, HertfordshireHospital not named in the registryContact: Galderma Research and DevelopmentTaking people
- WolverhamptonHospital not named in the registryContact: Galderma Research and DevelopmentTaking people
- York, YorkshireHospital not named in the registryContact: Galderma Research and DevelopmentTaking people
About the trial
What the trial wants to find out
The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.
The group in the trial
- Nemolizumab
Participants with moderate-to-severe AD who are receiving nemolizumab (Nemluvio®) in routine clinical practice will be observed for approximately 12 months.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Plain-language title
- Tracks nemolizumab use in adolescents and adults with atopic dermatitisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 13 March 2026